We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 486

Competition commission conditionally approves Sun-Ranbaxy deal
  • Vaish Associates Advocates
  • India
  • May 14 2015

In a December 5 2014 order the Competition Commission conditionally approved the proposed merger between Sun Pharma and Ranbaxy, subject to the


Generics vs. patented drugs
  • KASS International
  • India, Malaysia
  • April 27 2015

India's incredible advancement in various fields of technology (including launching its own first ever Mars mission!) has attracted other nations to


Patent controller revokes Boehringer’s patent based on Cipla’s post-grant opposition
  • Lakshmikumaran & Sridharan
  • India
  • April 15 2015

In its latest rejection of a pharmaceutical patent the Patent Office rejected Patent 254813, granted to Boehringer Ingelheim Pharma Gmbh, in a


Pharmaceuticals & healthcare newsletter - April 2015
  • Baker & McKenzie
  • India, Malaysia, Singapore
  • April 6 2015

The Singapore Ministry of Health (the "MOH") recently issued a set of National Telemedicine Guidelines (the "NTG"). Telemedicine is the systematic


Cipla-Novartis is revocation a reasonable solution?
  • LexOrbis Consulting Pvt Ltd
  • India
  • March 20 2015

On October 21 2014 Cipla, one of India's largest generic drug manufacturers, sought revocation of five of Novartis's patents under Sections 66 and 92


Compulsory patent licensing
  • Saikrishna & Associates
  • India
  • March 20 2015

IP jurisprudence is based on the premise of a quid pro quo between innovators and the state. An innovator which is granted a limited monopoly by way


Biosimilar litigation and its impact on IP strategy
  • Perfexio Legal
  • India
  • March 20 2015

A ‘biosimilar’ is a biological product that is highly similar to an existing approved biological product (notwithstanding minor differences in


The Indian medical device industry - regulatory, legal and tax overview
  • Nishith Desai Associates
  • India
  • March 19 2015

The Indian medical devices sector is worth approximately USD 3 Billion and is growing at a CAGR of 15. The medical devices market in India is


India
  • Krishna & Saurastri Associates
  • India
  • February 13 2015

The manufacture, distribution, labelling, packaging, sale or stocking of any drug in India is regulated by the Drugs and Cosmetics Act 1940. Under the


Delhi High Court sets aside Patent Office order rejecting Gilead’s patent application for Hepatitis C drug Solvadi on procedural grounds
  • Khaitan & Co
  • India
  • February 4 2015

On 30 January 2015, the Delhi High Court set aside an order dated 13 January 2015 (Order) of the Indian Patent Office (IPO) rejecting a patent to